InBody Scholar

InBody continues to work closely with academic researchers on a global scale to develop more in-depth clinical applications of body composition. With our long history in the industry, we provide more than 6,000 research publications. Research title with ★ indicates InBody recommended paper.

Anamorelin (ONO-7643) in Japanese patients with non-small cell lung cancer and cachexia: results of a randomized phase 2 trial

Body Composition Assessment
Takayama K et al.
Used Parameters : Body composition

Publication Year : 2016

Country : Japan

Journal : Support Care Cancer

Purpose Cancer cachexia is characterized by decreased body weight (mainly lean body mass [LBM]) and negatively impacts quality of life (QOL) and prognosis. Anamorelin (ONO-7643) is a novel selective ghrelin receptor agonist under development for treating cancer cachexia. Methods In this double-blind, exploratory phase 2 trial, we examined the efficacy and safety of anamorelin in Japanese patients (n= 181) with non-small cell lung cancer (NSCLC) and cancer cachexia (≥ 5% weight loss within the previous 6 months). The …
Full text